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ABSTRACT 
Introduction 
High rates of co-occurring depression are reported in Autism Spectrum Disorder (ASD), a 
neurodevelopmental condition characterised by social communication impairments and repetitive 
behaviours.  Cognitive behavioural interventions adapted for ASD have been effective for anxiety 
problems.  There have been evaluation studies of group CBT for co-occurring depression, but no 
randomised trials investigating low intensity psychological interventions as  recommended  in clinical 
guidelines for mild-moderate depression.  
Methods and Analysis 
A feasibility study comprising a randomised controlled trial (RCT) and nested qualitative evaluation is 
underway as preparation for a definitive RCT.  Participants (n=70) will be randomised to Guided Self-
Help (GSH): a low intensity psychological intervention based on Behavioural Activation adapted for 
ASD or Treatment as Usual (TAU). Outcomes including depression symptoms, anxiety, social function, 
and service use will be measured at 10, 16 and 24 weeks post randomisation and will be blind to group 
allocation for measures that are not self-administered. The analysis will aim to establish the rates of 
recruitment and retention for a larger scale RCT as well as the most appropriate measure of depression 
to serve as primary outcome. The qualitative study will purposively sample up to 24 participants from 
each treatment group to consider the acceptability and feasibility of the intervention and the trial 
design.  
Ethics and Dissemination 
Ethical approval has been received from WALES REC 3 (IRAS project ID: 191558) and the Health 
Research Authority with R&D approval from Avon and Wiltshire Mental Health Partnership (AWP) and 
Northumberland, Tyne & Wear (NTW) NHS Trusts   To our knowledge, this is the first study of a low 
intensity intervention for depression in adults with Autism. The results will inform the design of a 
definitive RCT.  Dissemination will include peer-reviewed journal publications reporting the 
quantitative and qualitative research findings of the study, and presentations at national and 
international conferences.    
Trial Registration: Current Controlled Trials ISRCTN54650760 assigned 28/09/2016 
http://www.isrctn.com/ISRCTN54650760 
Keywords:  Autism, Depression, Cognitive Behaviour Therapy, Low intensity intervention, Randomised 
Controlled Trial 
Strengths and Limitations: 
 This trial is funded following a commissioned call and thus aims to fill a clearly perceived 
clinical research and service gap 
 Recruitment procedures ensure diagnostic validity of Autism Spectrum Disorder (ASD) and 
depression 
 Conclusions about effectiveness or efficacy of the intervention are not possible 
 Inclusion of clinician as well as self-report measures of depression symptoms aims to 
overcome the documented difficulties with self-report of emotional states in ASD 
 Patient and Public Involvement in the development of the intervention  
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BACKGROUND 
Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterised by qualitative 
impairments in social communication and a pattern of restricted, repetitive behaviour, interests or 
activities[1].   High rates of co-occurring mental health problems have been reported in studies of 
children[2] and adults[3] with ASD.   These include depression, a common mental disorder 
characterised by persistent low mood, feelings of guilt and low self-worth, an absence of positive 
affect and disturbances in sleep, appetite, concentration and energy levels.  Depression is a 
debilitating mental health problem and has been estimated as the leading cause of loss of disability 
adjusted life years (DALYS) due to mental health and substance use disorders[4].  The estimated life-
time prevalence for a depressive episode for adults aged 16-74 in the U.K general population was 2.3% 
[5].  To date, there have been no robust epidemiological studies of depression in ASD but studies of 
clinical and research samples have reported high rates.  For example a clinical study of 122 autistic 
adults with ASD found that 53% met criteria for depression at some point in their lives[6].    A recent 
systematic review reported rates of depression ranging from 4% to 35% across 7 studies of autistic 
adults without intellectual disability[7].   Although sampling and measurement methods may 
contribute to the lack of consistent findings across studies, there is some evidence to suggest that the 
prevalence of depression is notably higher in autistic adults than the general population.    
The National Institute for Health and Care Excellence (NICE) Clinical Guidelines 90[8] recommend a 
stepped-care model for the treatment of depression.  Mild-moderate depression should be treated 
according to Step 2 of the care pathway i.e. low intensity psychosocial interventions, psychological 
interventions, medication and referral for further assessment and treatment. Low-intensity 
interventions aim to increase access to evidence based psychological therapies.  They are 
characterised by the provision of evidence based information, delivered by a range of ‘technologies’ 
such as written materials or computerised protocols, and facilitated by a mental health worker 
without formal professional training or self-facilitated.  Monitoring and review are also important.  
Low intensity psychological interventions for depression as recommended by the clinical guidelines[8] 
are individual guided self-help based on the principles of cognitive behavioural therapy (CBT) to 
include behavioural activation and problem-solving techniques, computerised CBT (cCBT) or a 
structured group physical activity programme.  
Cognitive Behavioural Therapy (CBT) refers to a group of psychological interventions which combine 
behavioural, cognitive and affect-focused techniques to bring about a reduction in psychological 
distress and an improvement in associated functional impairment.  Adaptations to the delivery and 
content of CBT are outlined in the clinical guidance for adults with Autism[9]. Recent systematic 
reviews indicate that CBT can be effective in reducing anxiety problems in young people[10,11] and 
adults with ASD[12] if adapted.  Meta-analysis of the studies of adapted CBT interventions for 
emotional disorders in children and adults report small-medium effect sizes (g= 0.24 on self-report 
outcomes, g= 0.66 on informant measures and g= 0.73 on clinician rated outcomes)[13].     
Despite the high rates of co-occurring depression and the success in evaluating the effectiveness of 
adapting CBT for anxiety problems, there is a paucity of systematic evidence for its usefulness in 
treating depression in ASD.  There have been 2 randomised evaluations of group CBT for young people 
with ASD using wait-list and cross-over trial designs[14,15] with mixed findings reported in respect of 
changes on the primary outcome measures and relatively small sample sizes.  An adult study[16] 
reported a significant effect of time but not treatment group on anxiety and depression measures 
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when comparing a CBT intervention with Mindfulness Based Stress Reduction (MBSR) both adapted 
for ASD.  There are then suggestions that CBT adapted for ASD may be effective for adults with co-
occurring depression, but to our knowledge, there have been no published clinical effectiveness 
studies of individual cognitive behavioural interventions, including Behavioural Activation or of a low 
intensity intervention.   
Clinical trials aside, naturalistic treatment evaluations are less well described and reported.  Thus, it is 
not known whether adults with ASD and co-occurring mild-moderate depression routinely access CBT 
interventions offered in primary care or experience less favourable treatment outcomes. It is known 
that the materials for low intensity CBT for depression have not been specifically developed with this 
group in mind.    
Aims: 
As part of a commissioned call by the NIHR HTA, this was a feasibility study for a large-scale 
Randomised Controlled Trial (RCT) that would determine the clinical and cost-effectiveness of a low 
intensity intervention for co-occurring depression in adults with autism.  The aims of the feasibility 
study were to:  
 Develop a low-intensity intervention for depression adapted for ASD based on NICE 
recommendations and accompanying training materials to guide therapists in supporting the 
intervention 
 Investigate the feasibility and patient and therapist acceptability of the low intensity 
intervention.  
 Estimate the rates of recruitment and retention for a large scale randomised controlled trial 
(RCT)  
 Identify the most appropriate outcome measure for a large scale RCT 
 
METHOD 
Trial Design  
The trial will comprise a single-blind, randomised controlled trial (RCT), with a nested qualitative 
evaluation. Participants will be randomly assigned to 1 of 2 treatment arms, a low-intensity 
intervention, Guided Self-Help for depression  adapted for adults with Autism (GSH), or Treatment as 
Usual (TAU).  
Recruitment 
Participants (n=70) will be recruited from Adult Autism clinics (n=2) and research organisations for 
adults with ASD (n=2).  
Inclusion Criteria 
 Aged ≥ 18 years 
 Clinical diagnosis of Autism Spectrum Disorder (ASD) 
 Current depression as measured by PHQ-9 score ≥ 10 
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Exclusion Criteria 
 Participants who are non-English speaking  
 Participants with literacy levels such that the written materials are inaccessible 
 Risk of suicide such that a low intensity intervention is not in line with clinical need 
 History of Psychosis 
 Current alcohol/substance dependence 
 Untreated epilepsy 
 Attended > 6 sessions of individual CBT during the previous 6 months 
Procedure 
Clinicians in the NHS Adult Autism Clinics will introduce the study to potentially eligible participants. 
Co-ordinators of the 2 research pathways will introduce the study to potentially eligible participants 
by mailshot, inviting people to find out more about the study according to the research opportunity 
protocols and guidelines.   
Potentially eligible participants who express an interest in the study will be invited to contact the 
research team to find out more. Eligibility screening according to the inclusion and exclusion criteria 
will then be conducted by telephone.   Participants meeting the inclusion/exclusion criteria will be 
invited to a meeting where eligibility will be confirmed using the Clinical Interview Schedule-Revised 
(CIS-R)[17], a standardised interview conducted by the researcher.  
Fully informed, written consent to participate in the study will be sought.  The researcher will ask 
participants to summarise in their own words what taking part in the study will involve, including 
enquiring about their understanding of the voluntary nature of the study.  
Baseline assessment will be completed face to face for all consenting participants and include a 
number of self-report measures of depression, anxiety, obsessive compulsive symptoms, quality of 
life, social function, rumination, repetitive behaviours and a current use of services  questionnaire (see 
Measures section).  A clinician administered depression measure will also be completed, the Hamilton 
Rating Scale for Depression (HRSD).  
A preferred communication and research contact strategy will be agreed with each individual at the 
outset of their participation in the study. As well as working with individual preferences, the aim is to 
minimise any retention issues occurring as a result of core characteristics of ASD.  Individual 
preferences may involve carers or other family members, a sole reliance on electronic communication, 
repeated reminders etc.  
Randomisation 
Eligible and consenting participants will be randomly allocated to GSH (n=35) or TAU (n=35) via a 
remote computerised randomisation service.  Randomisation will be stratified by NHS regional centre 
(n=2), and minimised by depression severity (mild-moderate, i.e. PHQ-9 scores between 10 and 15, or 
moderate-severe, i.e. PHQ-9 scores between 16 and 27) and anti-depressant medication (currently 
taking/not taking).   The trial manager will share details of the outcome of randomisation with the 
individual participants according to their communication preferences within 48 hours, and with the 
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therapist. Follow-up measurement will be carried out by researchers who will remain blind to 
treatment allocation (See Figure 1 for timeline of events).  
Figure 1 about here 
Randomised treatments 
Guided Self-Help 
The intervention is based on the principles of Behavioural Activation for depression, adapted for ASD 
and delivered as a low intensity intervention.  
The intervention will be delivered over 10 weeks. The first session (0) is a Planning session to orient 
the participant to the nature of guided self-help and the therapist to the nature of the participant’s 
ASD.  Individualised goals for treatment are formulated during this session.  Sessions 1- 4 contain 
information and tasks to facilitate learning about the importance of links between situations, 
behaviour and feelings. Activity scheduling to increase opportunities for positive mood, in line with 
treatment goals, form the basis for sessions 5-8.  Session materials are written with visual cues to 
enhance the accessibility of the text. A consistent session format is maintained throughout the 
treatment.  Feedback and advice about the materials during development was obtained from 2 adults 
with ASD.  They provided feedback about the clarity and acceptability of the written text, 
accompanying visual images, suggested homework tasks, the content of examples used to convey 
concepts, the visual layout and format of the written materials, and the amount of material provided 
for each individual session.   A focus group of adults with ASD was then asked to provide feedback on 
the final version of the Planning session and the study information sheets.   
Therapist ‘guides’ will facilitate the sessions, encouraging participants to review and reflect on the 
session materials, and plan homework tasks. Therapist guides will be unqualified psychologists with a 
foundation knowledge in CBT consistent with the knowledge and skills of low-intensity therapists. 
They will include assistant psychologists and clinical psychologists in training. They will not ordinarily 
have the knowledge and training to deliver individual, formulation-driven CBT.  Therapists will receive 
15 hours of training in the intervention and 1 hour minimum of clinical supervision on a weekly basis. 
Supervision will be delivered by qualified clinical psychologists who have developed the intervention. 
It can be face to face or remote (via telephone/Skype) and can be delivered on an individual or group 
basis.  A therapist manual has been developed for the intervention.  
The intervention will be delivered face to face, with sessions lasting up to 45 minutes. The exception 
is the initial planning session which can last up to 90 minutes to facilitate engagement. The 
intervention can be delivered by telephone or Skype if it is otherwise inaccessible to a participant. 
However it is designed to be delivered face to face, with the latter sessions (5-8) amenable to delivery 
by telephone if preferred.  Participants who attend ≥ 5 sessions will be considered to have received a 
minimally effective dose of treatment.  
Sessions will not be audio or video recorded.  Therapists will complete a session record at the end of 
each session listing the treatment components covered in the session, engagement with the session, 
ease of completion of the session tasks and extent to which any homework tasks were completed.  
This will allow post-hoc evaluation of any logistical and pragmatic issues arising with the session 
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materials. Progress with individual client treatment goals will be rated by the client on a scale of 0-10 
in Sessions 0, 4 and 8.    
Session by session measures will be completed, comprising the PHQ-9, GAD-7, brief Positive and 
Negative Affect Scale and engagement with daily activities. This will simulate routine practice in low 
intensity interventions where ongoing monitoring is an important element.  
Treatment as Usual 
There will be no restrictions on the care that can be provided as Treatment as Usual (TAU).  
Participants randomised to TAU will be provided with information about how to self-refer to local IAPT 
services. TAU may comprise no treatment, self or GP referral to IAPT services, Adult Autism clinic 
recommending GP referral to IAPT services, Adult Autism Clinic or GP referral to secondary mental 
health services, and/or anti-depressant medication. TAU will be carefully recorded in terms of the 
timing and nature of any intervention received.   
Eligibility Measure 
Clinical Interview Schedule – Revised (CIS-R)[17, ] The CIS-R is a structured diagnostic interview which 
generates ICD-10 psychiatric diagnoses. The CIS-R is a widely used, well validated diagnostic 
instrument.  The CIS-R was administered via a computerised questionnaire in this study to assess the 
inclusion and exclusion criteria alongside the PHQ-9 score.  
Outcome Measurement  
Follow-up assessment will be conducted at 10, 16 and 24 weeks post-randomisation (See table 1 for 
a full schedule of assessment measures by time point) and will be carried out by researchers blind to 
treatment allocation.  One aim of the study is to identify the most appropriate outcome measure for 
a large scale RCT, thus it is not possible to specify the primary outcome measure of depression a 
priori.  The feasibility of delivering the intervention over 10 weeks will be evaluated. Thus it is not 
clear if 10 or 16 weeks post-randomisation will represent the most effective point of outcome 
measurement i.e. if the majority of participants are unable to complete the intervention within 10 
weeks.  
Depression Measures 
The Patient Health Questionnaire (PHQ-9)[18] The PHQ-9 is a nine-item self-report measure of 
depression, which is commonly used in primary care settings. The PHQ-9 has been found to be reliable 
(Cronbach’s α=0.84-0.93), valid, and sensitive to change in the general population [19]. To the authors’ 
knowledge the psychometric properties of the scale have not been investigated with the autistic 
population.  
Beck Depression Inventory-II (BDI-II)[20] The BDI-II is a widely used, 21 -item self-report measure of 
depression. The BDI-II has been found to be reliable (Cronbach’s α=0 .92) for outpatients[20]. A 
validation study of 50 young people with ASD[21] reported good internal consistency on the BDI-II 
(Cronbach’s alpha=0.90).   
GRID-Hamilton Rating Scale for Depression (GRID-HAMD-17)[22] The GRID-HAMD is a version of the 
Hamilton Depression Rating Scale[23].  It is a 17-item clinician administered interview which has been 
found to be reliable and valid in the general population[22] but to our knowledge has not been 
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investigated in the autistic population.  GRID-HAMD interviews will be audio recorded with participant 
consent. Recordings will be independently rated by a second rater for all items (excluding items 8 and 
9 which require face to face assessment i.e. observation of psychomotor retardation and agitation) to 
establish reliability of each assessor. This will be done for the first 6 interviews conducted by each 
assessor.  To establish reliability across the study, a random sample (20%) of GRID-HAMD recordings 
will be independently rated.  
 
Participant Global Rating of Change – Participants are asked to rate whether their depression is better, 
worse or much the same on a 5 point scale at 16 and 24 week follow-up.  
 
Other Measures 
General Anxiety Disorder Questionnaire (GAD-7)[24] The GAD-7 is a seven-item self-report measure of 
anxiety. The scale has been found to be reliable and valid in the typically developing population [24], 
(Cronbach’s α=0.92). However the psychometric properties for use with autistic individuals is not 
known.  
Positive and Negative Affect Schedule (PANAS)[25] The PANAS is a 20-item self-report scale of positive 
and negative affect. The scale has been found to be reliable with a Cronbach’s alpha of .89 for the 
positive affect scale, and .85 for the negative affect scale[25] but has not been used with autistic 
individuals.  
 
Obsessive Compulsive Inventory-Revised (OCI-R)[26] The OCI-R is an 18-item self-report measure of 
the symptoms of obsessive-compulsive disorder, with items such as “I feel I have to repeat certain 
numbers”, which are scored on a five-point likert scale (0-4), indicating increasing frequency. The scale 
has been found to be reliable and valid[26].  The OCI-R has been found to have good psychometric 
properties in a sample of 225 autistic people[27]. 
 
Work and Social Adjustment Scale (WSAS)[28] The WSAS is a five-item self-report measure of impaired 
functioning which has been found to be reliable (Cronbach’s α=0.7-0.94) and valid in typically 
developing individuals.  It has been used with autism populations, but its psychometric properties 
have not been assessed. 
EQ-5D-5L [29] The EG-5D-5L is a five-item self-report measure of health, with items measured on a 
five-point likert scale (1-5) indicating severity. It has been found to be reliable and valid in the typically 
developing population[30].  
12-Item Short Form Health Survey (SF-12)[31] The SF-12 is a 12-item self-report measure of physical 
and mental health . It has been found to be a reliable and valid measure among people with severe 
mental health problems[32], but psychometric properties for autistic populations are not available. 
The Repetitive Behavours Questionnaire (RBQ-2A)[33] The RBQ-2A is a 20 item self-report measure of 
repetitive behaviours. It has been found to have good internal consistency, with Cronbach alphas 
between 0.73-0.83, and autistic people score significantly higher on the measure than typically 
developing individuals, suggesting that it is a valid measure of autism-specific repetitive behaviours.  
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The Rumination-Reflection Questionnaire (RRQ)[34] The RRQ is a  12-item self-report questionnaire, 
comprising 2 sub-scales; rumination and reflection. The measure has good psychometric properties, 
and the rumination scale has a cronbach’s alpha of .90, and the reflection scale .91.  
Economic evaluation - We will  pilot the feasibility of data collection on statutory health and voluntary 
service use using a questionnaire collecting information on: use of other primary and community care 
services (NHS Direct, attendances at walk-in centres, use of community health care services); 
secondary care related to mental health (number of out-patient visits, type of clinic, and reason for 
visit; inpatient stays, length of stay and reason); use of social services and disability payments received; 
personal costs related to mental health (expenditure on over-the-counter medication, expenditure on 
prescriptions, travel costs associated with health care visits, loss of earnings, out of pocket 
expenditure on other services e.g. private counselling or complementary or alternative therapies, child 
care and domestic help); time off work and unpaid activities. We will also access GP records to provide 
information on: number of primary care consultations, by type e.g. face-to-face, telephone etc., and 
who seen; and prescribed medication.  
 
Table 1.Timing of outcome measurement 
Measure Baseline  GSH Group 
Each Session 
10 
weeks(End 
of 
intervention) 
16 
weeks 
24 
weeks 
Demographics √     
PHQ-9 √ √ √ √ √ 
CIS-R √     
BDI √  √ √ √ 
SIGH-D √  √ √ √ 
GAD-7 √ √ √ √ √ 
OCI-R √   √ √ √ 
PANAS √  √ √ √ √ 
SF-12 √  √ √ √ 
EQ-5D-5L √  √ √ √ 
Participant Global 
Rating of Change 
   √ √ 
RBQ-2 √     
RRQ √  √   
Economic 
evaluation 
  √ √ √ 
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Statistical analysis  
We will be following the recently published extension to CONSORT[35] when reporting the results of 
this feasibility trial.  As this is a feasibility study there is no formal sample size calculation.  Seventy 
participants was considered a large enough sample to consider the practicalities of recruitment and 
delivering the intervention.  
For this feasibility study, we will calculate and present in a CONSORT flow-chart:  
1. the proportion of adults with ASD consenting to the study;  
2. the proportion completing the baseline assessment and entering the randomised phase;  
3. for those in the intervention group, the number of guided self-help sessions attended and the 
proportion completing 5 or more sessions;  
4. the proportion completing follow-up assessments at 10, 16 and 24 weeks post-randomisation.  
 
We will explore the sensitivity to change of the various self-reported measures of depression in 
comparison with the GRID-HAMD (clinician rated assessment of depression) in order to identify the 
most appropriate outcome measures for the main trial. We will also compare the continuous scores 
on the depression outcome measures between groups. The standard deviation of the chosen primary 
outcome will inform the sample size calculation for the large-scale RCT. 
We will evaluate the service use and economic evaluation questionnaire by examining the rates of 
completion across individual questions. We will compare the information provided by participants 
about primary and secondary care health service use with information gathered from GP and 
secondary care records.  
Qualitative study 
In-depth interviews will be conducted with participants (from both arms of the trial) 10 weeks after 
randomisation (after 10 week outcome measurement is complete). These interviews will consider and 
compare views and experiences of the trial and the acceptability of the guided self-help intervention. 
All therapists delivering the intervention will also be interviewed towards the end of the trial to 
illuminate the perceived effectiveness and acceptability of treatments and explore any barriers to its 
uptake outside of the trial. 
Purposive sampling will select interviewees in order to attempt to capture maximum variation in views 
and experiences in order that they adequately reflect those of a range of participants. All participants 
in the trial will be asked if they are willing to be contacted about taking part in a qualitative interview 
at the time of trial consent. From participants who indicate that they are willing to be contacted, a 
purposive sample will be drawn in relation to (i) the trial site, (ii) arm of the trial and (iii) socio-
demographic variables such as age, gender, ethnicity and socio-economic status (with participants 
being selected from areas of high and low social-economic deprivation, based on Index of Multiple 
Deprivation (IMD2007) score[36].  Interviews will be analysed in batches, and sampling will continue 
until no new themes are emerging from the interviews. This is likely to include up to 24 participants 
as well as 2-3 therapist interviews.   
All interviews will be conducted by telephone or face-to-face in a location of the participants’ choice. 
At interview, a flexible topic guide will be used to ensure primary issues are covered during all 
interviews, but without dictating data collection, allowing participants to introduce unanticipated 
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issues. Interviews are expected to last between 45-60 minutes. With informed consent, interviews will 
be recorded using a digital voice recorder, transcribed and anonymized.   
Interview transcripts will be checked for accuracy and then imported into NVivo10 qualitative data 
analysis software[37], to aid management and indexing of data. Thematic analysis[38] utilising a data-
driven inductive approach[39] will be used to scrutinise the data in order to identify and analyse 
patterns and themes of particular salience for participants and across the dataset using constant 
comparison techniques[40].  Analysis will begin shortly after data collection starts, will be ongoing and 
iterative. Analysis will inform further data collection: for instance, analytic insights from data gathered 
in earlier interviews will help identify any changes that need to be made to the topic guide during later 
interviews. Transcripts from the participants and therapists’ interviews will be analysed separately, 
with coding frames being developed for each. A subset of transcripts will be independently double-
coded by other members of the research team and compared. Discrepancies will be discussed and 
resolved to achieve a coding consensus. 
Monitoring and adverse events 
Adverse events and risk standardised operating procedures have been developed and will be followed 
by all researchers and therapists working on the trial. Adverse events are defined as significant 
negative episodes, or significant deterioration in condition, which happen to participants during their 
time in the trial. These will be reported by research assistants and trial therapists to senior trial staff, 
who will ascertain whether these are thought to be linked to participation in the trial, and keep records 
of each event on an adverse events database.  All serious adverse events of an unexpected and 
unrelated nature will be reported to the main Research Ethics Committee, the study Sponsor and Trial 
Steering Committee (TSC).   Suicide risk will be monitored using the suicidality items on the PHQ-9 and 
BDI-II which are administered at baseline, and 10- 16- and 24-week follow-up. If the participant states 
that they have had suicidal/self-harming thoughts every day in the last week (PHQ-9) or that they 
would like to kill themselves, or would kill themselves if they had chance (BDI-II), then a letter will be 
sent to their GP highlighting the individual’s risk. If the individual is considered to be high risk, a 
qualified clinician may also follow-up by offering information to the participant regarding local crisis 
teams, and call the GP to ensure the information is shared in a timely manner.  
Independent Oversight 
A Trial Steering Committee and Data Monitoring and Ethics Committee (DMEC) will have independent 
oversight of the study, meeting at 6 monthly intervals with quarterly reports of adverse and serious 
adverse events.  
Potential Limitations 
The majority of participants in this study will receive a diagnosis of Autism Spectrum Disorder (ASD) 
during adulthood and thus may not be representative of all adults with ASD.  
Treatment as Usual (TAU) may vary considerably by geographical region and service factors may act 
as a potential confound.  
SUMMARY 
High rates of co-occurring depression, a debilitating mental health problem, have been reported in 
adults with ASD[6].  There has been little research to date about the usefulness of adapted cognitive 
 
 
12 
 
behaviour therapy for depression in autism or about routine service outcomes for this group. This 
feasibility study aims to develop a low intensity intervention for depression for adults with autism 
based on cognitive behavioural principles and accompanying therapist guidelines and training. The 
study design will enable the research team to consider the feasibility of carrying out a large-scale 
randomised controlled trial to consider the effectiveness of the intervention, including specifying the 
most appropriate primary outcome measure. The nested qualitative study will address issues of 
patient and therapist acceptability of the intervention.  
Trial status 
The pilot RCT is currently open to recruitment and the last participant is scheduled to be randomised 
by the end of September 2017.  The trial will run until the end of April 2018. 
The full trial protocol can be accessed at  
https://www.journalslibrary.nihr.ac.uk/programmes/hta/144302#/ 
Competing Interests 
 Drs Cooper, Ensum, Gaunt, Horwood,  Kessler, Parr, Rai and Russell have nothing to disclose; Dr Barton 
reports grants from NIHR,  during the conduct of the study; Dr. Metcalfe reports grants from UK National 
Institute of Health Research HTA programme, during the conduct of the study; Dr Barry Ingham is a 
consultant clinical psychologist employed by an NHS Trust which has received external funding (NIHR 
and charities) to support his involvement in adult autism research projects; Dr. Wiles reports grants 
from University of Bristol, during the conduct of the study. 
Figure 1: Timeline of Events 
REFERENCES 
1 American Psychiatric Association Diagnostic and statistical manual of mental disorders (5th 
ed.) Washington, DC 2009. 
2 Mannion, A, and Leader, G  Co-morbidity in Autism Spectrum Disorder: A Review Res Autism 
Spectr Disord 2013; 7:1595-1616 
3 Russell, AJ, Murphy, CM, Wilson, E et al. Short Report:  The mental health of individuals 
referred for assessment of autism spectrum disorder in adulthood: A clinic report Autism 
2016; 20(5): 623-627 
4 Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental 
and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 
2013; 382(9904): 1575-86. 
5 McManus, S, Meltzer, H, Brugha, T, Bebbington, P. and Jenkins, R. (Editors) Adult 
Psychiatric Morbidity in England: results of a Household Survey The NHS Information Centre 
2009 
6 Hofvander, B, Delorme, R, Chaste, P, et al.  Psychiatric and psychosocial problems in adults 
with normal-intelligence autism spectrum disorders BMC Psychiatry 2009; 9: 35; 1-9 
7 Wigham S, Barton S, Parr JR et al. A systematic review of the rates of depression in children 
and adults with high functioning autism spectrum disorder Journal of Mental Health 
Research in Intellectual Disabilities 2017; 10(4): 267-287. 
8 NICE Clinical Guidelines 90 (CG90) Depression in adults: recognition and management  
National Institute for Healthcare and Excellence 2009 
9 NICE Clinical Guidelines 142 (CG142) )  Autism Spectrum Disorder in adults: recognition and 
management  National Institute for Healthcare and Excellence 2012 
 
 
13 
 
10 Lang, R., Regester, A, Lauderdale, S et al. Treatment of anxiety in autism spectrum disorders 
using cognitive behaviour therapy: A systematic review Developmental Rehabilitation 2010; 
13(1): 53-63 
11 Sukhodolsky, DG, Bloch, MH, Panza, KE et al. Cognitive behavioural therapy for anxiety in 
children with High-Functioning Autism: A Meta-analysis Pediatrics 2013; 132(5):1341-1350 
12 Spain, D, Sin, J, Chalder, T,  et al. Cognitive behaviour therapy for adults with autism spectrum 
disorders and psychiatric co-morbidity: A Review Res Autism Spectr Disord 2015; 9: 151-162 
13 Weston, L, Hodgekins, J, & Langdon, P E.  Effectiveness of cognitive behavioural therapy 
with people who have autistic spectrum disorders: A systematic review and meta-analysis. 
Clin Psychol Rev 2016; 49: 41–54 
14 Santomauro, D, Sheffield, J and Sofronoff, K Depression in adolescents with ASD: A pilot 
RCT of a group intervention J Autism Dev Disord 2016; 46(2):572-588 
15 McGilliveray, JA and Evert, HT Group cognitive behavioral program shows potential in 
reducing symptoms of depression and stress among young people with Autism Spectrum 
Disorders J Autism Dev Disord 2014; 44: 2041-51 
16 Sizoo, BB and Kuiper, E.  Cognitive Behaviour Therapy and Mindfulness Based Stress Reduction 
may be equally effective in reducing anxiety and depression in adults with Autism Spectrum 
Disorder Res Dev Disabil 2017; 64: 47-55 
17 Lewis, G, Pelosi, AJ, Araya, R et al. Measuring psychiatric disorder in the community: a 
standardized assessment for use by lay interviewers. Psychol Med 1992; 22(2): 465-486. 
18 Kroenke, K, & Spitzer, RL. The PHQ-9: a new depression diagnostic and severity 
measure. Psychiatr Ann 2002; 32(9):509-515 
19 Cameron, I M, Crawford, JR, Lawton, K et al. Psychometric comparison of PHQ-9 and HADS 
for measuring depression severity in primary care Br J Gen Pract 2008; 58(546): 32-36 
20 Beck, A T, Steer, R A, & Brown, G K (1996) Beck Depression Inventory-II. San Antonio, 1996 
21 Gotham, K, Unruh, K and Lord, C. Depression and its measurement in verbal adolescents and 
adults with autism spectrum disorder Autism 2015; 19(4): 491-504 
22 Williams, J B, Kobak, K A, Bech, P et al. The GRID-HAMD: standardization of the Hamilton 
depression rating scale. Int Clin Psychopharmacol 2008; 23(3):120-129.  
23 Hamilton, M. (1960) A Rating Scale for Depression J Neurol Neurosurg Psychiatry 1960; 23: 56  
24 Spitzer, R L, Kroenke, K, Williams, J B et al. A brief measure for assessing generalized 
anxiety disorder: the GAD-7 Arch Intern Med 2006;166(10):1092-1097. 
25 Crawford, J R & Henry, J D The Positive and Negative Affect Schedule (PANAS): Construct 
validity, measurement properties and normative data in a large non‐clinical sample Br J Clin 
Psychol 2004; 43(3): 245-265. 
26 Foa, E B, Huppert, J D, Leiberg, S et al The Obsessive-Compulsive Inventory: development 
and validation of a short version Psychol Assess 2002; 14(4): 485 
27 Cadman, T, Spain, D, Johnston,P, et al Obsessive-compulsive disorder in adults with high-
functioning autism spectrum disorder: what does self-report with the OCI-R tell us?  Autism 
Res 2015; 8(5): 477-85 
28 Mundt, J C, Marks, I M, Shear, M K et al. The Work and Social Adjustment Scale: a simple 
measure of impairment in functioning Br J Psychiatry 2002;180(5):461-464 
29 Herdman, M, Gudex, C, Lloyd, A et al. Development and preliminary testing of the new five-
level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20(10):1727-1736 
30 Janssen, M F, Birnie, E, Haagsma, J A et al. (2008). Comparing the standard EQ-5D three-
level system with a five-level version. Value in Health 2008;11(2):275-284 
31 Ware, JE, Kosinski, M, and Keller, SD (1996) A 12-item short-form Health Survey (SF-12): 
Construction of scales and preliminary test of reliability Medical Care 1996; 32(3): 220-233 
 
 
14 
 
32 Salyers, M P, Bosworth, H B, Swanson, J W et al. Reliability and validity of the SF-12 health 
survey among people with severe mental illness. Medical care 2000;38(11):1141-1150 
33 Barrett, S L, Uljarević, M, Baker, E K et al.  The Adult Repetitive Behaviours Questionnaire-2 
(RBQ-2A): a self-report measure of restricted and repetitive behaviours. J Autism Dev Disord 
2015;45(11): 3680-3692 
34 Trapnell, P D, & Campbell, J D Private self-consciousness and the five-factor model of 
personality: distinguishing rumination from reflection. J Pers Soc Psychol 1999;76(2): 284 
35 Eldridge, SM, Chan, CL. Campbell, MJ et al. CONSORT 2010 Statement: extension to 
randomised pilot and feasibility trials BMJ 2016; MJ,355:i5239 
http://dx.doi.org/10.1136/bmj. i5239 
36 Noble, M, McLennan, D, Wilkinson, K et al. The English Indices of Deprivation 2007  
Communities and Local Government Publications; 2008 
37 NVivo qualitative data analysis Software; QSR International Pty Ltd. Version 10, 2012 
38 Braun V. & Clarke V. Using thematic analysis in psychology. Qual Res Psychol 2006;3:77-101 
39 Boyatzis, R. Transforming qualitative information: Thematic analysis and code development. 
Thousand Oaks, CA: Sage 1998 
40 Charmay K. Constructing grounded theory: a practical guide through qualitative analysis. 
London: Sage 2006 
 
 
